5 Best Quality Stocks To Own For 2015

For MoneyShow’s Jim Jubak, there seems to be no end to the excitement of the EuroZone crisis these days, as it appears that the turmoil is, practically, hopping from one European nation to another these days, as can be deduced, given the recent EuroZone finance ministers’ meetings.

I want to know who scripts the meetings of EuroZone finance ministers?

Whoever it is gets maximum drama out of a deadly dull event.

So, here we have the ministers meeting yesterday in Athens—the scene of the almost meltdown in the euro.

The lead item from the meeting is that the finance ministers have ended a six-month bailout standoff and approved an 8.3 billion euro ($11.4 billion) bailout package for Greece, with the first 6.3 billion scheduled for payout by the end of April. The deal comes just in time to pay a 9.3 billion bond due in May. (Most of that, by the way, is due to the European Central Bank.)

The deal became possible when the Greek parliament passed, on Sunday night—by one vote—a set of reforms demanded by the country’s international creditors at the European Central Bank, the European Commission, and the International Monetary Fund.

5 Best Quality Stocks To Own For 2015: Digital Cinema Destinations Corp (DCIN)

Digital Cinema Destinations Corp., incorporated on July 29, 2010, operates eight theatres and 73 screens located in Westfield, New Jersey (Rialto), Cranford, New Jersey (Cranford), Bloomfield, Connecticut (the Bloomfield 8) and five theatres located in central Pennsylvania (Cinema Centers). During the fiscal year ended June 30, 2012 (fiscal 2012), the Company operates eight theatres, two in New Jersey, with a total of 11 screens, one in Connecticut, with a total of 8 screens and five in central Pennsylvania, with a total of 54 screens. In March 2014, the Company announced that it has completed the acquisition of a seven screen theater in Churchville, MD from Flagship Cinemas.

The Rialto is a six-screen theatre located in downtown Westfield, New Jersey, which has a population of approximately 30,000 people. The Bloomfield 8 is an eight-screen theatre located at the Wintonbury Mall in the town of Bloomfield, Connecticut, which is a New England town of over 20,00 0 people that is home to many sites that are on the National Register of Historic Places and is approximately 5.5 miles from downtown Hartford, Connecticut. Cinema Centers consists of a chain of five theatres with 54 screens located throughout central Pennsylvania. All of the Cinema Centers theatres are in free zones. The 11-screen Cinema Center of Bloomsburg theatre is located in Bloomsburg, Pennsylvania. Bloomsburg, a college town of approximately 13,000 people, is located midway between Wilkes Barre and Williamsport, Pennsylvania. The 12-screen Cinema Center of Camp Hill theatre is located in Camp Hill, Pennsylvania, just outside of Harrisburg, Pennsylvania. Harrisburg is the state capital of Pennsylvania with a population of approximately 50,000 people.

The 10-screen Cinema Center at Fairgrounds Square Mall is located in Reading, Pennsylvania. The Company’s Cinema Centers, had one digital projector, RealD 3D enabled. The 12-screen Cinema Center at Selinsg rove is located in Selinsgove, Pennsylvania. Selinsgrove is ! a historic town located on the Susquehanna River with a population of approximately 27,000 people located within five miles of the theatre. The nine-screen Cinema Center of Williamsport is located in Williamsport, Pennsylvania.

The Company competes with Regal Entertainment Group, AMC Entertainment Inc., Clearview and Cinemark USA, Inc.

Advisors’ Opinion:

  • [By Erin McCarthy]

    Carmike Cinemas Inc.(CKEC), the nation’s fourth-largest movie theater chain, said Thursday it is acquiring Digital Cinema Destinations Corp.(DCIN), a smaller rival that does business as Digiplex.

5 Best Quality Stocks To Own For 2015: iShares 1-3 Year Treasury Bond ETF (SHY)

iShares Lehman 1-3 Year Treasury Bond Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the short-term sector of the United States Treasury market as defined by the Lehman Brothers 1-3 Year U.S. Treasury Index (the Index). The Index includes all publicly issued United States Treasury securities that have a remaining maturity of between 1 and 3 years, are non-convertible, are denominated in United States dollars, are rated investment grade (Baa3 or better) by Moody’s Investors Service, are fixed rate, and have $250 million or more of outstanding face value. Excluded from the Index are certain special issues, such as flower bonds, targeted investor notes (TINs), and state and local government bonds (SLGs), and coupon issues that have been stripped from assets already included in the Index.

The Index is a market capitalization-weighted index. The Fund invests in a representative sample of the securities in the Index, which has a similar investment profile as the Index. The Fund’s investment advisor is Barclays Global Fund Advisor.

Advisors’ Opinion:

  • [By Donald van Deventer]

    Shorter-duration Treasury Exchange-Traded Funds: (SHY), (SHV), (IEI), (BIL), (TUZ), (FIVZ), (DTUL), (VGSH), (DTUS), (DFVS), (DFVL), (SST), (ISTB), (TBZ).

5 Best Quality Stocks To Own For 2015: Cree Inc.(CREE)

Cree, Inc. develops and manufactures light emitting diodes (LEDs), LED lighting, and semiconductor solutions for wireless and power applications. Its LED products include blue and green LED chips that are used in various applications, including video screens, gaming displays, function indicator lights, and automotive backlighting; LED components comprising a range of packaged LED products and LED modules for lighting applications; LED lighting products, such as LED downlights, LED troffers, and LED lamps or bulbs for construction, retrofit, and renovation projects in commercial, governmental, and residential applications; and silicon carbide (SiC) wafers, which are used in the manufacture of optoelectronics, microwave, power switching, and other applications. The company also provides semiconductor materials and devices primarily based on silicon carbide (SiC), gallium nitride (GaN), and related compounds. Its power and radio frequency (RF) products include SiC-based power products comprising 600, 1,200, and 1,700-volt Schottky diodes, as well as 1,200-volt SiC metal semiconductor field-effect transistor switches that are used in power factor correction circuits for power supplies in computer servers and other applications, such as solar inverters; and RF devices, including a range of GaN high electron mobility transistors and monolithic microwave integrated circuits for military or commercial applications, as well as 10 watt and 60 watt SiC transistors and metal semiconductor field effect transistor products. The company primarily operates in China, the United States, Europe, South Korea, Japan, Malaysia, and Taiwan. Cree, Inc. was formerly known as Cree Research, Inc. and changed its name in January 2000. Cree, Inc. was founded in 1987 and is based in Durham, North Carolina.

Advisors’ Opinion:

  • [By rusticnomad]

    After more than a year when an outperformance rating was given on Cree (CREE), it has turned out to be an overachiever with 112% returns. Cree is a LED lighting company which has always focused on delivering the best performance at the lowest cost.

  • [By Vinay Singh]

    LED specialist Cree (CREE) crashed after the company’s guidance for the current quarter turned out to be weaker than expected. Cree’s management is looking to capture more market for its LED products, a space where bigger players such as General Electric and Philips also operate.

  • [By Rich Bieglmeier]

    [Related -Cree, Inc. (CREE) Q2 Earnings Preview: What To Expect?]

    Cree develops and manufactures semiconductor materials and devices primarily based on silicon carbide (SiC), gallium nitride (GaN) and related compounds. It focuses on SiC and GaN on light emitting diode (LED) products. It develops lighting-class light emitting diode (LED) products, lighting products and semiconductor products for power and radio-frequency (RF) applications.

  • [By John Kell var popups = dojo.query(“.socialByline .popC”); popups.forEach(func]

    Cree Inc.(CREE) said its fiscal third-quarter earnings climbed 27% on higher sales of its lighting bulbs. Shares declined 7.4% to $53.75 premarket as the company’s outlook was mostly below views.

5 Best Quality Stocks To Own For 2015: Protalix Biotherapeutics Inc (PLX)

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX- 105.

Taliglucerase Alfa

Taliglucerase alfa is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. The Company has commenced pre-clinical studies of an oral form of taliglucerase alfa. Its oral taliglucerase alfa is a plant cell expressed form of GCD that is naturally encapsulated within carrot cells genetically engineered to express the GCD enzyme. Pre-clinical studies of oral taliglucerase alfa demonstrate the stability of the enzyme in the cell and the capacity of the cell’s cellulose wall to protect the enzyme against degradation in the digestive tract in an in-vitro model of the stomach and intestines. Additionally, rats fed with lyophilized carrot cells expressing GCD have accumulated the active enzyme in the target organs; the spleen and liver. As of December 31, 2010, the Company had completed Phase III Clinical Trial.

PRX-102

The Company is developing PRX-102, i ts plant cell expressed modified version of the recombinant ! alpha-GAL-A protein, a therapeutic enzyme for the treatment of Fabry disease. Fabry disease is a rare, hereditary, genetic lysosomal storage disorder in humans caused by an X-lined deficiency of the alpha-GAL-A enzyme. The Company is in the animal evaluation testing phase of the development of PRX-102, which tests are based on a mouse model for Fabry disease.

Acetylcholinesterase

Protalix Ltd. is a wholly owned subsidiary of the Company is licensed the rights to certain technology under a research and license agreement with Yissum Research and Development Company (Yissum) and the Boyce Thompson Institute, Inc. Pursuant to the agreement, the Company is developing PRX-105, a plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, as well as in a biodefense program and an organophosphate-based pesticide treatment program.

As of December 31, 2010, its in-vitr o experiments of PRX-105 have shown that the acetylcholinesterase enzyme in its ProCellEx protein expression system demonstrates biological activity on biochemical and cellular levels. In addition, early animal studies demonstrated that the acetylcholinesterase expressed in its ProCellEx protein expression system was able to treat animals exposed to the nerve gas agent analogues, both when injected with its acetylcholinesterase product candidate immediately before exposure or when injected after exposure. In March 2010, it initiated a preliminary phase I clinical trial of PRX-105, which the Company completed in June 2010.

pr-antiTNF

pr-antiTNF is a candidate for the treatment of certain autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing, spondylitis, psoriatic arthritis and plaque psoriasis. The Company has designed the antiTNF as pr-antiTNF. pr-antiTNF is a plant cell-expressed recombinant fusion protein ma de from the soluble form of the human TNF receptor (TNFR), f! used to t! he Fc component of a human antibody domain. pr-antiTNF has an identical amino acid sequence to Enbrel and its in-vitro and preclinical animal studies have demonstrated that pr-antiTNF exhibits similar activity to Enbrel. Specifically, pr-antiTNF binds TNF thereby inhibiting it from binding to cellular surface TNF receptors and protects L929 cells from TNF-induced apoptosis in a dose-dependent manner.

The Company competes with Genzyme, Actelion, Crucell N.V., Biolex, Inc., Chlorogen, Inc., Greenovation Biotech GmbH, Symbiosys, Novartis AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva.

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Industrial biotech isn’t the only industry headed to Brazil. Protalix (NYSEMKT: PLX  ) entered into a technology transfer agreement with Brazil’s Ministry of Health last week that will pay the company $280 million. The deal is big news for Protalix’s first product, Elelyso/Uplyso, which was developed with partner Pfizer (NYSE: PFE  ) . The treatment is approved as an enzyme replacement therapy, or ERT, for adults with type 1 Gaucher disease, and it marks a huge step forward for the future of biomanufacturing. In the following video, Fool contributor Maxx Chatsko explains what this means for the product’s commercialization and the adoption of Protalix’s novel plant cell-based expression system for therapeutic proteins.

  • [By Keith Speights]

    Other investors might wish that Pfizer would use some of its cash to acquire a few smaller companies. Protalix BioTherapeutics (NYSEMKT: PLX  ) has been mentioned as one possible candidate. The two companies already partner together on Gaucher disease drug Elelyso. In February, Protalix spurred rumors that Pfizer could be interested in buying the company after it announced that it had engaged Citigroup to pursue a “broad array of strategic alternatives.”

5 Best Quality Stocks To Own For 2015: Thinspace Technology Inc (THNS)

Thinspace Technology Inc., formerly Vanity Events Holding, Inc., incorporated on November 22, 2006, is a holding company. Utilizing their licensed trademark of America’s Cleaning Company, Vanity established a cleaning company offering residential and commercial cleaning services. In October 2012, the Company acquired fineartlender.com. In October 2012, the Company acquired additional URLS, which include Weddinggownlender.com; Suitlender.com and Bridalpartylender.com.

The Company seeks out, licenses, develops, promotes, and brings to market various consumer and commercial products. The Company markets products directly to the consumer and marketplace through one of its own properties www.ThereIsAProductForThat.com.

The Company competes with Rent the Runway, Inc., Rent-A-Center, Inc., Bag, Borrow or Steal, Inc., Aaron’s, and Gilt Groupe, Inc.

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap tech or media stocks Thinspace Technology Inc (OTCMKTS: THNS), Beamz Interactive Inc (OTCBB: BZIC) and Hannover House Inc (OTCMKTS: HHSE) have been getting some extra attention lately, but it appears that only one of these stocks has been the subject of a paid promotion. Nevertheless, all three stocks have been busy with press releases trying to get the attention of investors or traders. So are these three small cap tech or media stocks worth your attention? Here is a closer look along with a reality check:

    Thinspace Technology Inc (OTCMKTS: THNS) Was Recently Busy With Press Releases

    Small cap Thinspace Technology Inc is a global provider of reliable, scalable and affordable application delivery, virtualization and cloud client technology to public and private sector companies and organizations of all sizes. On Monday, Thinspace Technology Inc rose 2.80% to $0.330 for a market cap of $30.24 million plus THNS is down 82.6% over the past year and down 89.8% over the past five years according to Google Finance.

  • [By Peter Graham]

    Last Friday, small cap biotech or tech stocks Amanasu Techno Holdings Corp (OTCMKTS: ANSU), Bio Matrix Scientific Group Inc (OTCMKTS: BMSN) and Thinspace Technology Inc (OTCBB: THNS) surged 44.74%, 42.31% and 14%, respectively, with only one of these small caps appearing to be the subject of some sort of small paid promotions or investor relations campaign. Given the lack of a big pump from promoters or IR people, will these three small caps keep surging or will the tide go out again this week? Here is a quick reality check to help you decide on a trading or investing strategy: